Type 2 diabetes originated from non-alcoholic fatty liver disease

Abstract

Both non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are highly prevalent metabolic liver diseases. Accumulating epidemiological evidence now indicates that NAFLD and T2DM are strongly associated, yet the causative relationship remains to be elucidated. Liver serves as a hub for nutrient and energy metabolism in the body. Here we demonstrated the pathogenesis linking NAFLD to T2DM through a series of studies and the attenuation of T2DM progression after NALFD improvement in cohort study. We proposed the urgent necessity of NAFLD management and NAFLD drug development, which might be novel therapeutic avenues for T2DM.

Keywords

non-alcoholic fatty liver disease / gluconeogenesis / hepatokine / exercise

References

[1] Younossi ZM, Golabi P, de Avila Let al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:a systematic review and meta-analysis. J Hepatol 2019; 71: 793- 801.

[2] Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018; 14: 99- 114.

[3] Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018; 14: 88- 98.

[4] Loomba R, Abraham M, Unalp Aet al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943- 51.

[5] Mantovani A, Petracca G, Beatrice Get al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus:an updated meta-analysis of 501 022 adult individuals. Gut 2021; 70: 962- 9.

[6] Yamazaki H, Tsuboya T, Tsuji Ket al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 2015; 38: 1673- 9.

[7] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021; 397: 2212- 24.

[8] Jarvis H, Craig D, Barker Ret al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD):a systematic review and meta-analysis of population-based observational studies. PLoS Med 2020; 17: e1003100.

[9] Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease:biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679- 89.

[10] Lu Y, Ma Z, Zhang Zet al. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 2014; 63: 170- 8.

[11] Xiong X, Wang X, Lu Yet al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 2014; 60: 847- 54.

[12] Wang X, Lu Y, Wang Eet al. Hepatic estrogen receptor alpha improves hepatosteatosis through upregulation of small heterodimer partner. J Hepatol 2015; 63: 183- 90.

[13] Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017; 127: 1- 4.

[14] Lu Y, Wang E, Chen Yet al. Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activat glucocorticoid ion of receptor. J Clin Invest 2020; 130: 3791- 804.

[15] Liu B, Zhang Z, Hu Yet al. Sustained ER stress promotes hyperglycemia by increasing glucagon action through the deubiquitinating enzyme USP14. Proc Natl Acad Sci U S A 2019; 116: 21732- 8.

[16] Pal D, Dasgupta S, Kundu Ret al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 2012; 18: 1279- 85.

[17] Zhao J, Xiong X, Li Yet al. Hepatic F-box protein FBXW7 maintains glucose homeostasis through degradation of fetuin-A. Diabetes 2018; 67: 818- 30.

[18] Lu Y, Liu X, Jiao Yet al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest 2014; 124: 3501- 13.

[19] Zhang HJ, He J, Pan LLet al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease:a randomized clinical trial. JAMA Intern Med 2016; 176: 1074- 82.

[20] Chen Y, Chen Z, Pan Let al. Effect of moderate and vigorous aerobic exercise on incident diabetes in obese adults:a 10-year follow-up of a randomized controlled trial. JAMA Intern Med 2023; 183: 272- 5.

[21] Holmer M, Lindqvist C, Petersson Set al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet-a randomised controlled trial. JHEP Rep 2021; 3: 100256.

[22] Goldenberg JZ, Day A, Brinkworth GDet al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission:systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 2021; 372: m4743.

[23] Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021; 17: 484- 95.

RIGHTS & PERMISSIONS

2023 The Author(s) 2023. Published by Oxford University Press on behalf of Higher Education Press.